Atossa Therapeutics (ATOS)
NASDAQ:ATOS

Atossa Therapeutics Stock Analysis & Ratings

ATOS Stock Chart & Stats

Day’s Range$0.84 - $0.898899
52-Week Range$0.84 - $9.80
Previous Close$0.88
Volume1.65M
Average Volume (3M)1.94M
Market Cap$107.74M
P/E Ratio-4.9
Beta1.98
Next EarningsAug 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-0.17


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ATOS FAQ

What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $0.83 and its highest was $9.80 in the past 12 months.
    What is Atossa Therapeutics’s market cap?
    Atossa Therapeutics’s market cap is $107.74M.
      What is Atossa Therapeutics’s price target?
      The average price target for Atossa Therapeutics is $8.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $8.00 ,the lowest forecast is $8.00. The average price target represents 840.18% Increase from the current price of $0.851.
        What do analysts say about Atossa Therapeutics?
        Atossa Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Atossa Therapeutics’s upcoming earnings report date?
          Atossa Therapeutics’s upcoming earnings report date is Aug 15, 2022 which is in 81 days.
            How were Atossa Therapeutics’s earnings last quarter?
            Atossa Therapeutics released its earnings results on May 09, 2022. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.01.
              Is Atossa Therapeutics overvalued?
              According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
                Does Atossa Therapeutics pay dividends?
                Atossa Therapeutics does not currently pay dividends.
                What is Atossa Therapeutics’s EPS estimate?
                Atossa Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Atossa Therapeutics have?
                Atossa Therapeutics has 126,620,000 shares outstanding.
                  What happened to Atossa Therapeutics’s price movement after its last earnings report?
                  Atossa Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went up 3.158%.
                    Which hedge fund is a major shareholder of Atossa Therapeutics?
                    Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.

                      ---

                      Atossa Therapeutics Stock Analysis

                      The Atossa Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Atossa Therapeutics

                      Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Biocept
                      Seelos Therapeutics
                      AVEO Pharma
                      Soleno Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis